Alsultan 2021.

Methods	Trial design: randomised trial Sample size: 49 Setting: inpatient Language: English Number of centres: 1 Type of intervention: treatment
Participants	Inclusion criteria: adult (aged ≥ 18 years) positive PCR test of COVID‐19 virus in specimens taken from the respiratory tracts, and people with negative PCR test but had clinical signs and symptoms of viral illness with chest CT scan showing the radiological findings of viral pneumonia, which was defined as new, unexplained, and bilateral infiltrates on the lungs Exclusion criteria: people admitted to hospital for other conditions with oxygen saturation ≥ 94% without viral symptoms but had infiltrations on chest CT scan (mild form of COVID‐19) received other antiviral or investigational therapies for COVID‐19 died or transmitted to ICU during the first 24 hours people who presented with persistent treatment of corticosteroid inhalers
Interventions	Intervention group: inhaled budesonide 200 µg, twice daily for 5 days + supportive care Control group: supportive care (oxygen supplementation, vitamins, anticoagulants, dexamethasone, prone position, non‐invasive ventilation (CPAP or BIPAP), antibiotics, and fluids) Concomitant therapy: no
Outcomes	No distinction between primary and secondary outcomes: time of hospitalisation (mean), time on oxygen supplementation from admission to cure (mean), admission PiO2/FiO2 ratio vs discharge PiO2/FiO2 ratio (mean), admission oxygen saturation + oxygen supplementation vs discharge oxygen saturation (mean)
Notes	Recruitment status: completed Prospective completion date: not stated Date last update was posted: not stated Sponsor/funding: not stated